Immunization

Childhood immunization, achieved through vaccinations, is essential to protect children from severe illness, disability, and death from vaccine-preventable diseases. Data on vaccination coverage are used to identify groups at risk of vaccine-preventable diseases, monitor trends in vaccination over time, and evaluate the effectiveness of interventions designed to increase coverage.

Indicator HC3.A Percentage of children who, by age 24 months, have completed the combined 7-vaccine series by poverty status, birth years 2011–2020
Indicator HC3.A: Percentage of children who, by age 24 months, have completed the combined 7-vaccine series by poverty status, birth years 2011–2020

NOTE: The combined 7-vaccine series includes 4 doses or more of diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), 3 doses or more of poliovirus vaccine, 1 dose or more of measles-containing vaccine, the full series of Haemophilus influenzae type b conjugate vaccine (Hib), 3 doses or more of hepatitis B vaccine (HepB), 1 dose or more of varicella vaccine (VAR), and 4 doses or more of pneumococcal conjugate vaccine (PCV). The recommended immunization schedule for children is available at https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html. Poverty status is based on family income and household size using U.S. Census Bureau poverty thresholds for the year of data collection. National Immunization Survey—Child data for the 2020 birth year are from survey years 2021, 2022, and 2023.

SOURCE: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, National Immunization Survey—Child.

Indicator HC3.B Percentage of adolescents ages 13–17 years with routinely recommended-for-age vaccinations, survey years 2011–2023
Indicator HC3.B: Percentage of adolescents ages 13–17 years with routinely recommended-for-age vaccinations, survey years 2011–2023

NOTE: The routine vaccination recommendation for adolescents beginning at ages 11–12 includes tetanus-diphtheria-acellular pertussis vaccine (Tdap), meningococcal conjugate vaccine (MenACWY), and human papillomavirus (HPV) vaccine (2 or 3 doses, depending on when first dose is received).The recommended immunization schedule for adolescents is available at https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html.

SOURCE: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, National Immunization Survey—Teen.

  • Among children born in 2020, 68% had received the combined 7-vaccine series (4:3:1:3*:3:1:4) by age 24 months. The percentage who received this vaccine series was lower for those in families with incomes below the poverty threshold (58%) than for those in families with incomes at or above the poverty threshold (71%).
  • Among children born since 2011, the total percentage who received the combined 7-vaccine series by age 24 months has remained steady (approximately 68%). Disparity in coverage by poverty status has persisted.
  • In 2023, 77% of adolescents ages 13–17 years received one dose or more of the human papillomavirus (HPV) vaccine, and 61% were up to date on the HPV vaccine series.1
  • In 2023, the proportion of adolescents ages 13–17 years who received one dose or more of the HPV vaccine (77%) was lower than the percentages who received one dose or more of the other two routinely recommended adolescent vaccinations: tetanus, diphtheria, and acellular pertussis (Tdap) (89%) and meningococcal conjugate (MenACWY) (88%).

table icon HC3.A HTML Table | HC3.B HTML Table

1 Up to date is three doses of the HPV vaccine or two doses of the HPV vaccine when the first dose is received prior to age 15 years and there is at least 5 months minus 4 days between the first and second dose.

Federal Interagency Forum on Child and Family Statistics

Explore

More Information

Contact